205 related articles for article (PubMed ID: 25580850)
1. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
2. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
6. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
7. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
8. [Anti-Tumor Effect of Rigosertib on HEL and K562 Cells and Its Related Mechanism].
Xu F; Chang CK; Li X; He Q; Wu LY; Zhang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1362-1366. PubMed ID: 29070108
[TBL] [Abstract][Full Text] [Related]
9. In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.
Lu T; Laughton CA; Wang S; Bradshaw TD
Mol Pharmacol; 2015 Jan; 87(1):18-30. PubMed ID: 25316768
[TBL] [Abstract][Full Text] [Related]
10. The novel synthesized 2-(3-(methylamino)phenyl)-6-(pyrrolidin-1-yl)quinolin-4-one (Smh-3) compound induces G2/M phase arrest and mitochondrial-dependent apoptotic cell death through inhibition of CDK1 and AKT activity in HL-60 human leukemia cells.
Huang SM; Yang JS; Tsai SC; Chen MH; Hsu MH; Lin HY; Chou LC; Chinag JH; Lee KH; Huang LJ; Kuo SC
Int J Oncol; 2011 May; 38(5):1357-64. PubMed ID: 21344160
[TBL] [Abstract][Full Text] [Related]
11. 6,7-Dimethoxy-3-(3-methoxyphenyl)isoquinolin-1-amine induces mitotic arrest and apoptotic cell death through the activation of spindle assembly checkpoint in human cervical cancer cells.
Chung KS; Choi HE; Shin JS; Cho YW; Choi JH; Cho WJ; Lee KT
Carcinogenesis; 2013 Aug; 34(8):1852-60. PubMed ID: 23615402
[TBL] [Abstract][Full Text] [Related]
12. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
[TBL] [Abstract][Full Text] [Related]
13. Dependency of 2-methoxyestradiol-induced mitochondrial apoptosis on mitotic spindle network impairment and prometaphase arrest in human Jurkat T cells.
Lee ST; Lee JY; Han CR; Kim YH; Jun do Y; Taub D; Kim YH
Biochem Pharmacol; 2015 Apr; 94(4):257-69. PubMed ID: 25732194
[TBL] [Abstract][Full Text] [Related]
14. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner.
Huang J; Yang M; Liu H; Jin J
Acta Pharmacol Sin; 2008 Aug; 29(8):951-64. PubMed ID: 18664328
[TBL] [Abstract][Full Text] [Related]
15. ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.
Dai YH; Hung LY; Chen RY; Lai CH; Chang KC
Transl Res; 2016 Sep; 175():129-143.e13. PubMed ID: 27150054
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
[TBL] [Abstract][Full Text] [Related]
17. A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway.
Wang TE; Wang YK; Jin J; Xu BL; Chen XG
Int J Oncol; 2014 Aug; 45(2):771-81. PubMed ID: 24859921
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
[TBL] [Abstract][Full Text] [Related]
19. Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.
Mäki-Jouppila JH; Laine LJ; Rehnberg J; Narvi E; Tiikkainen P; Hukasova E; Halonen P; Lindqvist A; Kallio L; Poso A; Kallio MJ
Mol Cancer Ther; 2014 May; 13(5):1054-66. PubMed ID: 24748653
[TBL] [Abstract][Full Text] [Related]
20. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition.
Wang FZ; Chang ZY; Fei HR; Yang MF; Yang XY; Sun BL
Biochimie; 2014 Aug; 103():118-25. PubMed ID: 24793486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]